Stocks › VRTX

VERTEX PHARMACEUTICALS INC / MA

VRTX·Nasdaq·United States United States·USD
$515.02
-5.64 (-1.08%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
VRTX
VERTEX PHARMACEUTICALS INC / MA · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
VRTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of VRTX by members of U.S. Congress · 98 on record · 16 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Sale
$1,001 - $15,000
Nov 5, 2026 Oct 7, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Oct 8, 2026 Sep 4, 2026 Filing ↗
David J. TaylorDavid J. TaylorHouse · R · OH VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Sale
$1,001 - $15,000
Sep 5, 2026 Aug 26, 2026 Filing ↗
Tommy TubervilleTommy TubervilleSenate · R · AL VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Sale
$1,001 - $15,000
Aug 5, 2026 May 3, 2024 Filing ↗
Alan ArmstrongAlan ArmstrongSenate · R · OK VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Jul 21, 2026 Mar 27, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$1,001 - $15,000
Jul 7, 2026 Jun 2, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Sale
$1,001 - $15,000
Jun 10, 2026 May 27, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$1,001 - $15,000
May 11, 2026 Apr 24, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$1,001 - $15,000
May 11, 2026 Apr 13, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Sale
$1,001 - $15,000
Apr 7, 2026 Mar 30, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Apr 7, 2026 Mar 23, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Sale
$15,001 - $50,000
Mar 9, 2026 Feb 5, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$1,001 - $15,000
Feb 6, 2026 Jan 23, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$15,001 - $50,000
Feb 6, 2026 Jan 29, 2026 Filing ↗
David J. TaylorDavid J. TaylorHouse · R · OH VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Sale
$1,001 - $15,000
Feb 2, 2026 Jan 29, 2026 Filing ↗
Julia LetlowJulia LetlowHouse · R · LA VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Jan 13, 2026 Oct 23, 2024 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$1,001 - $15,000
Nov 6, 2025 Oct 7, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Oct 3, 2025 Sep 29, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Sale
$1,001 - $15,000
Oct 3, 2025 Sep 5, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Common Stock Purchase
$1,001 - $15,000
Sep 9, 2025 Aug 4, 2025 Filing ↗
David J. TaylorDavid J. TaylorHouse · R · OH VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Sep 2, 2025 Aug 7, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Sale
$1,001 - $15,000
Aug 13, 2025 Jun 10, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Sale
$1,001 - $15,000
Aug 13, 2025 Jun 11, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Aug 13, 2025 Dec 11, 2024 Filing ↗
Ro KhannaRo KhannaHouse · D · CA VRTXVERTEX PHARMACEUTICALS INC / MA · Stock Purchase
$1,001 - $15,000
Jul 9, 2025 Jun 23, 2025 Filing ↗

Whale Activity

Position changes in VRTX reported for 2026-09-30 by 1901 institutional filers
Increased: 759New: 149Held: 259Decreased: 557Closed: 101No prior filing: 76
  • Increased759
  • New149
  • Held259
  • Decreased557
  • Closed101
  • No prior filing76
FilerSharesValueChange
Capital World Investors26.0M$13.58Bdecreased
BlackRock, Inc.23.8M$12.44Bdecreased
Capital Research Global Investors17.8M$9.31Bdecreased
VANGUARD CAPITAL MANAGEMENT LLC16.6M$8.68Bincreased
STATE STREET CORP12.0M$6.29Bincreased
Invesco Ltd.8.3M$4.33Bincreased
GEODE CAPITAL MANAGEMENT, LLC6.1M$3.17Bincreased
JPMORGAN CHASE & CO5.7M$3.00Bdecreased
Capital International Investors5.1M$2.65Bincreased
VANGUARD PORTFOLIO MANAGEMENT LLC4.9M$2.59Bincreased
FRANKLIN TEMPLETON INC4.5M$2.45Bincreased
LOOMIS SAYLES & CO L P3.6M$1.89Bdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by VRTX insiders, by quarter · Form 4
-200.0K-100.0K0100.0K200.0K2025 Q1: -39.1K2025 Q12025 Q2: -4522025 Q22025 Q3: 14.7K2025 Q32025 Q4: -159.1K2025 Q42026 Q1: -159.1K2026 Q12026 Q2: -21.0K2026 Q22026 Q3: -3,8692026 Q32026 Q4: -28.4K2026 Q4

Recent Insider Transactions

5,938 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Thornberry NancyDirector · Director Sale −1,000 $547.86 $548K Nov 16, 2026 Form 4 ↗
Bhatia Sangeeta N.Director · Director Sale −271 $547.86 $148K Nov 16, 2026 Form 4 ↗
WAGNER CHARLES F JREVP, CO & FO Sale −15.3K $547.87 $8.4M Nov 12, 2026 Form 4 ↗
Kewalramani ReshmaCEO & President · Director Sale −11.9K $531.53 $6.3M Nov 6, 2026 Form 4 ↗
van Grunsven JasperEVP, CP and NPPO Grant / award +8,682 $0.00 $0 Sep 8, 2026 Form 4 ↗
Ambrose KristenSVP & Chief Accounting Officer Grant / award +5,000 $0.00 $0 Aug 28, 2026 Form 4 ↗
SACHS BRUCE IDirector Gift −6,000 $0.00 $0 Aug 27, 2026 Form 4 ↗
Tatsis OuraniaEVP, Chief Reg. & Quality Off. Grant / award +8,251 $0.00 $0 Jul 21, 2026 Form 4 ↗
Sachdev AmitEVP Chief Patient & Ext Af Off Grant / award +8,251 $0.00 $0 Jul 21, 2026 Form 4 ↗
Tatsis OuraniaEVP, Chief Reg. & Quality Off. Sale −1,500 $524.99 $787K Jul 2, 2026 Form 4 ↗
McKechnie DuncanEVP, Chief Commercial Officer Sale −1,541 $519.00 $800K Jul 2, 2026 Form 4 ↗
Liu JoyEVP and Chief Legal Officer Sale −828 $502.71 $416K Jul 1, 2026 Form 4 ↗
Bozic CarmenEVP and CMO Sale −596 $482.50 $288K Jun 26, 2026 Form 4 ↗
Bozic CarmenEVP and CMO Sale −1,020 $462.17 $471K Jun 18, 2026 Form 4 ↗
Bozic CarmenEVP and CMO Sale −4,062 $450.00 $1.8M Jun 15, 2026 Form 4 ↗
Bozic CarmenEVP and CMO Sale −1,745 $450.00 $785K Jun 5, 2026 Form 4 ↗
Liu JoyEVP and Chief Legal Officer Sale −828 $439.91 $364K Jun 1, 2026 Form 4 ↗
Bozic CarmenEVP and CMO Sale −1,974 $450.00 $888K May 29, 2026 Form 4 ↗
Bunnage Mark E.EVP, Chief Scientific Officer Sale −33 $453.45 $15K May 15, 2026 Form 4 ↗
Bozic CarmenEVP and CMO Sale −1,354 $453.45 $614K May 15, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding VRTX · SEC Form N-PORT
FundSharesValue% of fundAs of
Growth Fund of America12.9M$7.03B1.99%Aug 31, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
8.1M$4.00B0.17%Jun 30, 2026
VANGUARD 500 INDEX FUND
VANGUARD INDEX FUNDS
6.6M$3.27B0.20%Jun 30, 2026
Investment Co of America6.3M$3.11B1.69%Jun 30, 2026
American Balanced Fund5.6M$2.76B0.96%Jun 30, 2026
Invesco QQQ Trust, Series 15.4M$2.68B0.55%Jun 30, 2026
AMCAP Fund4.7M$2.58B2.73%Aug 31, 2026
Fidelity 500 Index Fund
Fidelity Concord Street Trust
3.3M$1.79B0.21%Aug 31, 2026
iShares Core S&P 500 ETF
iShares Trust
3.5M$1.73B0.20%Jun 30, 2026
New Perspective Fund3.4M$1.67B0.98%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list VRTX's shares (CUSIP 92532F100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Capital Research Global InvestorsSCHEDULE 13G/A · passive (13G) · 17.8M shares7.0%
    Nov 13, 2026 · ↗
  • Capital World InvestorsSCHEDULE 13G/A · passive (13G) · 25.7M shares10.1%
    May 14, 2026 · ↗
  • Capital Research Global InvestorsSCHEDULE 13G/A · passive (13G) · 21.1M shares8.3%
    May 14, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming vertex pharmaceuticals as client
$0$2.5M$5.0M$7.5M$10.0M2023 Q1: $1.1M2023 Q2: $990K2023 Q3: $1.2M2023 Q4: $1.3M20232024 Q1: $1.6M2024 Q2: $1.5M2024 Q3: $1.4M2024 Q4: $1.4M20242025 Q1: $2.1M2025 Q2: $2.9M2025 Q3: $1.7M2025 Q4: $1.6M20252026 Q1: $1.7M2026 Q2: $1.8M2026 Q3: $1.8M2026
  • CGCN GROUP, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · HCR, MMM$50K
    Filing ↗
  • MARSHALL & POPP, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · MMM, TRD$60K
    Filing ↗
  • MCLARTY INBOUND LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · TRD$90K
    Filing ↗
  • AVENUE SOLUTIONSVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · MMM, HCR$60K
    Filing ↗
  • TARPLIN, DOWNS & YOUNG, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q3 · BUD, HCR, MMM$80K
    Filing ↗

Government Contracts

Federal awards to VERTEX PHARMACEUTICALS INC / MA · USAspending

No federal contract awards found for VERTEX PHARMACEUTICALS INC / MA.

U.S. Patents

Recent USPTO applications naming VERTEX PHARMACEUTICALS INC / MA

No USPTO patent applications found for VERTEX PHARMACEUTICALS INC / MA.

Annual Financials

From VRTX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$12.00B$11.02B$9.87B$8.93B$7.57B
Operating income$4.17B-$232.9M$3.83B$4.31B$2.78B
Net income$3.95B-$535.6M$3.62B$3.32B$2.34B
Diluted EPS$15.32-$2.08$13.89$12.82$9.01
Operating cash flow$3.63B-$492.6M$3.54B$4.13B$2.64B
Cash and equivalents$5.08B$4.57B$10.37B$10.50B$6.79B
Total assets$25.64B$22.53B$22.73B$18.15B$13.43B
Total liabilities$6.98B$6.12B$5.15B$4.24B$3.33B
Shareholders' equity$18.67B$16.41B$17.58B$13.91B$10.10B

As VERTEX PHARMACEUTICALS INC / MA tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 13, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 2-for-1Stock splitAug 24, 2000

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeOct 20, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 1, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 8.01, 9.01Material agreement · Reg FD disclosure · Other eventsJul 7, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 13, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
    EDGAR ↗

About VERTEX PHARMACEUTICALS INC / MA

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBOSTON, MA
IncorporatedMA